KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Assets (2017 - 2025)

Amneal Pharmaceuticals has reported Current Assets over the past 9 years, most recently at $1.9 billion for Q4 2025.

  • Quarterly results put Current Assets at $1.9 billion for Q4 2025, up 20.37% from a year ago — trailing twelve months through Dec 2025 was $1.9 billion (up 20.37% YoY), and the annual figure for FY2025 was $1.9 billion, up 20.37%.
  • Current Assets for Q4 2025 was $1.9 billion at Amneal Pharmaceuticals, up from $1.8 billion in the prior quarter.
  • Over the last five years, Current Assets for AMRX hit a ceiling of $1.9 billion in Q4 2025 and a floor of $1.3 billion in Q1 2023.
  • Median Current Assets over the past 5 years was $1.5 billion (2024), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Current Assets: fell 12.07% in 2021 and later grew 21.49% in 2025.
  • Amneal Pharmaceuticals' Current Assets stood at $1.5 billion in 2021, then dropped by 7.12% to $1.4 billion in 2022, then decreased by 2.41% to $1.4 billion in 2023, then increased by 15.24% to $1.6 billion in 2024, then rose by 20.37% to $1.9 billion in 2025.
  • The last three reported values for Current Assets were $1.9 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.6 billion (Q2 2025) per Business Quant data.